Scientists at the Sahlgrenska Academy have developed a new cancer treatment that has proved to be effective in mice. The treatment, which is presented in the prestigious scientific journal PNAS, is based on newly discovered properties of the so-called BET bromodomain inhibitors.
A few years ago, a molecule known as “JQ1” was developed, which can block so called BET bromodomain proteins. This switch off the known cancer gene MYC thereby preventing cancer cells from dividing.
Jonas Nilsson, Sahlgrenska Cancer Center at the University of Gothenburg
The discovery was regarded as a major breakthrough. A problem was that JQ1 did not function optimally in animal experiments, and this means that it has not been possible to test the treatment on cancer patients.
Jonas Nilsson and his research group have developed, in collaboration with the Canadian company Zenith epigenetics, a new molecule known as “RVX2135”, which has been tested in mice with MYC-driven lymphoma. The study will be published this week in the early edition of the prestigious scientific journal PNAS and shows that the new molecule not only causes cancer cells in culture to stop growing, it also causes tumors to die. This means that the mice survive their cancer longer.
“We hypothesized that the new molecule could also switch off the MYC gene. However, our studies show that neither the JQ1 molecule nor the RVX2135 molecule have this property in these types of cells. This means that the mode of action is probably not as simple as we believed,” says Jonas Nilsson, Group Leader at the Sahlgrenska Cancer Center.
Increased survival in mice
The scientists in Gothenburg also discovered that the RVX2135 molecule activates the same genes as those activated by molecules known as “HDAC inhibitors”, which are already used to treat cancer. The scientists then tested HDAC inhibitors together with the newly discovered molecules and it turned out that the combination increased survival in mice with lymphoma.
“It was also possible to reduce the dose of HDAC inhibitors when used in combination with RVX2135 and this reduced adverse effects. We see this as a breakthrough in the clinical development of this type of treatment,” Jonas Nilsson explains.
Jonas Nilsson has recently founded the Sahlgrenska Translational Melanoma Group together with surgeons and oncologists at the Sahlgrenska University Hospital. This group will investigate whether the treatment can be used also for malignant melanoma.
“The work is challenging, but we believe that the prospects for success with combination treatments are good,” says Jonas Nilsson.
The article BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma will be published online in Proceedings of the National Academy of Sciences on 16 June.
Link to article: http://www.pnas.org/content/early/2014/06/13/1406722111.abstract
More information about the research project: http://www.cancercenter.gu.se/research/nilsson-lab/
Jonas Nilsson, Sahlgrenska Cancer Center at the Sahlgrenska Academy, University of Gothenburg
Tel.: +46 31 786 6768
Cell: +46 73 027 3039
Henrik Axlid | idw - Informationsdienst Wissenschaft
On track to heal leukaemia
18.01.2017 | Universitätsspital Bern
Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).
Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...
10.01.2017 | Event News
09.01.2017 | Event News
05.01.2017 | Event News
18.01.2017 | Power and Electrical Engineering
18.01.2017 | Materials Sciences
18.01.2017 | Life Sciences